In focus · trending topic

SPR994

18 stories · following the connections

Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update

By Nasdaq OMXDec 14, 2017, 9:15 PM UTC

Spero Therapeutics Announces Underwriters’ Option Exercise

By Nasdaq OMXNov 13, 2017, 12:00 PM UTC

Spero Therapeutics Announces Closing of Initial Public Offering

By Nasdaq OMXNov 6, 2017, 9:01 PM UTC

Spero Therapeutics Announces Pricing of Initial Public Offering

By Nasdaq OMXNov 1, 2017, 10:00 PM UTC

Spero Therapeutics Launches Initial Public Offering

By Nasdaq OMXOct 23, 2017, 11:00 AM UTC

Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994

By Nasdaq OMXOct 20, 2017, 12:00 PM UTC

Spero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults

By Nasdaq OMXOct 10, 2017, 12:01 PM UTC

Spero Therapeutics Files Registration Statement for Proposed Initial Public Offering

By Nasdaq OMXOct 6, 2017, 8:27 PM UTC